1. A once-per-week regime of selinexor, bortezomib and dexamethasone was associated with significantly improved progression-free survival versus current standard of ...
1. Approximately a quarter of multiple myeloma patients that had refractory disease despite treatment with a proteasome inhibitor, immunomodulatory agent, ...
Multiple myeloma often develops from the precursor condition monoclonal gammopathy of undetermined significance (MGUS), which is detectable in peripheral blood. ...
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve ...
1. bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) proteins, was shown to achieve ...
Autologous stem cell transplantation (ASCT) is commonly used in the treatment of multiple myeloma, though relapse is extremely common. Ixazomib ...
1. Patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS) and followed for multiple decades showed shorter overall survival rates ...
1. The use of lenalidomide, bortezomib and dexamethasone (RVD) with transplantation was associated with a significantly longer progression-free survival compared ...
![Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2016/02/20541_lores-350x250.jpg)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma Daratumumab is a human monoclonal antibody that has shown efficacy and safety in ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
